Information and interesting ideas

Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.

Monday, July 17, 2023

Updates to the FDA’s Clinical Laboratory Improvement Amendments (CLIA) Web pages Make Processes Clearer, Easier to Understand

FDA just released information on the improvements to their website for users and FDA's role in establishing assay complexity standards:

--The Clinical Laboratory Improvement Amendments (CLIA) and the associated regulations provide the authority for oversight of clinical laboratories and laboratory testing. While the Centers for Medicare and Medicaid Services (CMS) is responsible for many aspects of the CLIA program, including the certification of clinical laboratories, the U.S. Food and Drug Administration (FDA) is responsible for categorizing the complexity of tests, and the categorization is then used to determine which laboratories can perform which tests.

The website: https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clinical-laboratory-improvement-amendments-clia?utm_medium=email&utm_source=govdelivery

 

No comments:

Post a Comment

FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made

This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...